• LAST PRICE
    58.4500
  • TODAY'S CHANGE (%)
    Trending Down-0.4400 (-0.7472%)
  • Bid / Lots
    58.3000/ 1
  • Ask / Lots
    58.5600/ 3
  • Open / Previous Close
    58.5400 / 58.8900
  • Day Range
    Low 57.9700
    High 58.6700
  • 52 Week Range
    Low 45.0500
    High 82.1600
  • Volume
    16,948
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 58.89
TimeVolumePCRX
09:32 ET394758.33
09:34 ET105158.24
09:36 ET70058.045
09:38 ET80058.24
09:39 ET80058.23
09:41 ET10058.2
09:43 ET10058.24
09:45 ET30058.2515
09:48 ET10058.49
09:50 ET170058.585
09:52 ET92358.55
09:54 ET30058.62
09:56 ET70058.45
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPCRX
Pacira Biosciences Inc
2.7B
73.1x
---
United StatesTLRY
Tilray Brands Inc
2.1B
-4.5x
---
United StatesCORT
Corcept Therapeutics Inc
3.0B
30.2x
+66.36%
United StatesHCM
HUTCHMED (China) Ltd
2.3B
-9.9x
---
United StatesAMPH
Amphastar Pharmaceuticals Inc
1.8B
23.1x
+43.27%
United StatesHRMY
Harmony Biosciences Holdings Inc
3.1B
56.2x
---
As of 2022-08-08

Company Information

Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company is engaged in advancing a pipeline of products across a range of therapeutic areas that include acute postsurgical pain; acute and chronic osteoarthritis (OA), pain of the knee; low back and other areas; spasticity and stellate ganglion block of the sympathetic nerves. The company is developing interventions to address debilitating conditions involving the sympathetic nervous system. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular, corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Contact Information

Headquarters
5401 West Kennedy Boulevard, Suite 890TAMPA, FL, United States 33609
Phone
813-553-6680
Fax
302-655-5049

Executives

Chairman of the Board, Chief Executive Officer
David Stack
Chief Financial Officer
Charles Reinhart
President - Rest of World
Max Reinhardt
Chief Operating Officer
Daryl Gaugler
Chief Administrative Officer, Secretary
Kristen Williams

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$2.7B
Revenue (TTM)
$614.3M
Shares Outstanding
45.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.84
EPS
$0.80
Book Value
$16.33
P/E Ratio
73.1x
Price/Sales (TTM)
4.4
Price/Cash Flow (TTM)
27.3x
Operating Margin
13.72%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.